204 results
Page 4 of 11
8-K
EX-2.1
9rkr3a985wga
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
8-K
c64 w5lmw
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
425
EX-2.1
a42t3gbbfokoptf
29 Mar 21
Business combination disclosure
7:27am
425
380sbvbhr134st
29 Mar 21
Business combination disclosure
7:27am
8-K
EX-99.1
xnikk t62h
5 Jan 21
Millendo Therapeutics Provides Pipeline and Business Update
9:08am
S-8
EX-5.1
m0isx
10 Nov 20
Registration of securities for employees
7:49am
8-K
EX-99.1
rtxd0wl4qy4lvlqaxn
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
EX-99.2
xtjuz0
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.1
gs40u8
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.1
jah1w f9dhgrifey
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
8-K
EX-1.1
a4bdrmrjmar bp8bn
4 Mar 20
Entry into a Material Definitive Agreement
8:37am
8-K
EX-99.1
9o0und0m9am
10 Feb 20
Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer
8:42am
8-K
EX-99.1
hgmzxxahx x5uqmgei
19 Dec 19
Geoff Nichol Appointed to Millendo Therapeutics Board of Directors
8:31am